Polycystic Liver Disease Clinical Trial
Official title:
Polycystic Liver Disease Registry (UK)
Multicentre, observational registry studying the natural course of polycystic liver disease.
The Polycystic Liver Disease (PLD) registry (UK) is the UK specific part of an international, multicentre, observational registry. The overall international PLD registry is led by Radboud University Medical Center, Nijmegan, Netherlands. Note- please direct any queries about the international registry to the team at Radboud University Medical Center. All patients with Polycystic Kidney Disease (PKD) with PLD or patients with Isolated (without PKD) Polycystic Liver Disease are eligible for inclusion (>10 liver cysts). Data will be collected prospectively and retrospectively including a specific validated PLD questionnaire (PLD-Q). This registry provides us insight in patient characteristics, risk factors, symptoms, quality of life and treatment strategies in the biggest international PLD cohort so far. Results of this registry will be published and shared at national and international congresses. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05215964 -
The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
|
||
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Recruiting |
NCT05500157 -
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
|
N/A | |
Completed |
NCT01354405 -
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
|
N/A | |
Completed |
NCT01315795 -
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05281328 -
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
|
Phase 2/Phase 3 | |
Recruiting |
NCT02173080 -
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
|
||
Completed |
NCT01157858 -
Everolimus and LongActing Octreotide Trial in Polycystic Livers
|
Phase 2 | |
Recruiting |
NCT05478083 -
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
|
Phase 2 | |
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Terminated |
NCT00934791 -
Polycystic Liver Disease in Kidney Transplant
|
N/A | |
Completed |
NCT02021110 -
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
|
Phase 2 | |
Completed |
NCT01670110 -
Pasireotide LAR in Severe Polycystic Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT00771888 -
Open-Label Extension of LOCKCYST Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT03960710 -
Automatic Segmentation of Polycystic Liver
|